ACG Wealth’s Edwards Lifesciences EW Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q3
Sell
-682
Closed -$65K 474
2022
Q2
$65K Sell
682
-3,400
-83% -$352K 0.01% 398
2022
Q1
$481K Sell
4,082
-2,160
-35% -$242K 0.09% 177
2021
Q4
$809K Hold
6,242
0.12% 170
2021
Q3
$707K Hold
6,242
0.09% 168
2021
Q2
$646K Buy
6,242
+2
+0% +$189 0.08% 175
2021
Q1
$522K Hold
6,240
0.07% 193
2020
Q4
$569K Hold
6,240
0.08% 176
2020
Q3
$498K Hold
6,240
0.08% 179
2020
Q2
$431K Hold
6,240
0.07% 179
2020
Q1
$392K Hold
6,240
0.07% 204
2019
Q4
$485K Hold
6,240
0.07% 212
2019
Q3
$457K Sell
6,240
-600
-9% -$42.1K 0.07% 221
2019
Q2
$421K Sell
6,840
-15
-0.2% -$907 0.06% 238
2019
Q1
$437K Buy
6,855
+15
+0.2% +$856 0.06% 224
2018
Q4
$349K Hold
6,840
0.05% 223
2018
Q3
$397K Hold
6,840
0.05% 218
2018
Q2
$332K Hold
6,840
0.05% 217
2018
Q1
$318K Hold
6,840
0.05% 223
2017
Q4
$257K Sell
6,840
-84
-1% -$3.08K 0.04% 269
2017
Q3
$252K Buy
+6,924
New +$264K 0.04% 223
2017
Q2
Sell
-6,840
Closed -$214K 328
2017
Q1
$214K Buy
+6,840
New +$214K 0.04% 251
2016
Q4
Sell
-6,240
Closed -$251K 266
2016
Q3
$251K Hold
6,240
0.05% 201
2016
Q2
$207K Buy
+6,240
New +$213K 0.05% 203

Other funds holding EW

ACG Wealth's EW Position: Q3 2022 in Review

ACG Wealth sold out of Edwards Lifesciences (EW) in Q3 2022, closing a stake of 682 shares — an estimated $65K sold.

ACG Wealth first reported a position in EW in Q2 2016 and held it in 23 quarters. The position peaked at $809K in Q4 2021. 1,246 funds tracked by Wall St. Rank hold EW as of Q3 2022.

  • ACG Wealth reported no remaining Edwards Lifesciences position as of Q3 2022 after selling out during the quarter.
  • ACG Wealth sold 682 Edwards Lifesciences shares in Q3 2022, an estimated $65K.
  • ACG Wealth first reported a position in Edwards Lifesciences in Q2 2016 and held it in 23 quarters.
  • ACG Wealth's Edwards Lifesciences position peaked at $809K in Q4 2021.
  • 1,246 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q3 2022.

Based on ACG Wealth's 13F filing for Q3 2022, filed 3 Nov 2022.